What are your top takeaways from SGO 2022?

So many great presentations at SGO 2022! The depth of the science was amazing and the ability to co-mingle in person with new friends and colleagues was more than fabulous. Although I am asked to discuss 3 pivotal abstracts, I encourage all readers to review the many great presentations via the “OnD...

My 3 most significant takeaways from the 2022 SGO Meeting on Women's Cancer:

1. Atezolizumab administered before and concurrently during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to the phase IB...

1. SIENDO. For patients without actionable and/or predictive biomarkers, maybe we can extend treatment-free intervals with a once-weekly maintenance therapy. I am curious how this will fit into the treatment algorithms.
2. Cost-effectiveness abstracts on Pembro for cervical cancer and dosing in lenvati...

1. SIENDO trial
2. SORAYA trial
3. Mersana ADC
4. HRD assay in Leuvin
5. Niraparib maintenance in PRIME trial.

1) NRG GY017: A Phase I/Ib trial conducted by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group NRG Oncology, concluded that the addition of the immunotherapy drug atezolizumab prior to and concurrently given with chemoradiation treatment was safe for women with node-...

1. Selinexor Mx in TP53wt - Endometrial
2. PRIME niraparib 1L HRP - Ovary
3. SORAYA or everything else (exciting meeting!)

The top abstract that I was excited about was the iPocc study which presented a PFS benefit for patients undergoing IP carboplatin, especially in the suboptimally debulked patient.

This was a long-awaited study, and its results are definitely thought-provoking. For myself and among other GOs I spok...

1. SIENDO
2. SORAYA
3. Cost-effectiveness dose-packaging Lenvatinib

My 3 most interesting abstracts included:

1. SORAYA: Mirvetuximab Soravtansine in platinum resistant recurrent ovarian cancer.

As a single agent in the PROC population, the identified ORR was promising and may establish this drug as an alternate treatment strategy for folate receptor alpha high patien...

I thought that the follow-up of the radical hysterectomy study presented by Dr. Ramirez would continue to have a major impact. (Plenary presentation on “Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis”)